Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease

[1]  N. Russell,et al.  Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis , 1998, Bone Marrow Transplantation.

[2]  M. Labopin,et al.  Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1996, Bone marrow transplantation.

[3]  K. Atkinson,et al.  Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. , 1995, Bone marrow transplantation.

[4]  A. Gratwohl,et al.  Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. , 1995, Blood.

[5]  H. Deeg,et al.  Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? , 1993, Blood.

[6]  H. Deeg,et al.  Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. , 1992, Blood.

[7]  F. Frassoni,et al.  Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. , 1991, Blood.

[8]  L. Pickle,et al.  Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. , 1991, Bone marrow transplantation.

[9]  G. Gahrton,et al.  Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. , 1991, Bone marrow transplantation.

[10]  H. Deeg,et al.  Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. , 1989, Blood.

[11]  R. Hoffmann,et al.  Risk factors for acute graft‐versus‐host disease , 1987, British journal of haematology.

[12]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[13]  J. Lipton,et al.  Efficacy of a short course (four doses) of methotrexate following bone marrow transplantation for prevention of graft-versus-host disease. , 1985, Transplantation.

[14]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.

[15]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.

[16]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .